Imunon-Entwicklungschef Khursheed Anwer tritt zurück

Reuters
Feb 05
Imunon-Entwicklungschef Khursheed Anwer tritt zurück

Imunon Inc. hat eine strategische Umstrukturierung angekündigt, bei der Stellen abgebaut werden, die nicht für die laufende Phase-3-Studie im Bereich Eierstockkrebs erforderlich sind. Zudem wird Khursheed Anwer, Executive Vice President und Chief Scientific Officer, mit Wirkung zum 20. Februar 2026 nach fast 12 Jahren im Unternehmen in den Ruhestand treten.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9649511) on February 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10